These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3762967)

  • 1. Cerebrospinal fluid C9 in demyelinating disease.
    Compston DA; Morgan BP; Oleesky D; Fifield R; Campbell AK
    Neurology; 1986 Nov; 36(11):1503-6. PubMed ID: 3762967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis.
    Morgan BP; Campbell AK; Compston DA
    Lancet; 1984 Aug; 2(8397):251-4. PubMed ID: 6146808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal component of complement (C9) in the cerebrospinal fluid of patients with multiple sclerosis and neurologic controls.
    Rodriguez M; Wynn DR; Kimlinger TK; Katzmann JA
    Neurology; 1990 May; 40(5):855-7. PubMed ID: 2330118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminal component of complement C9 in CSF and plasma of patients with MS and aseptic meningitis.
    Halawa I; Lolli F; Link H
    Acta Neurol Scand; 1989 Aug; 80(2):130-5. PubMed ID: 2816275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology.
    Polihronis M; Paizis K; Carter G; Sedal L; Murphy B
    J Neurol Sci; 1993 Apr; 115(2):230-3. PubMed ID: 8387101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cerebrospinal fluid proteins in multiple sclerosis.
    Rosenthal A
    Clin Lab Med; 1986 Sep; 6(3):457-75. PubMed ID: 3091313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.
    Jongen PJ; Lamers KJ; Doesburg WH; Lemmens WA; Hommes OR
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):446-51. PubMed ID: 9343121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid and neuropathological study in Devic's syndrome. Evidence of intrathecal immune activation.
    Leonardi A; Arata L; Farinelli M; Cocito L; Schenone A; Tabaton M; Mancardi GL
    J Neurol Sci; 1987 Dec; 82(1-3):281-90. PubMed ID: 3440870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid immunoglobulin G in childhood. Measurement by electroimmunodiffusion.
    Nellhaus G
    Arch Neurol; 1971 May; 24(5):441-8. PubMed ID: 4995260
    [No Abstract]   [Full Text] [Related]  

  • 10. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications.
    McLean BN; Luxton RW; Thompson EJ
    Brain; 1990 Oct; 113 ( Pt 5)():1269-89. PubMed ID: 2245296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid lipidomic biomarker signatures of demyelination for multiple sclerosis and Guillain-Barré syndrome.
    Péter M; Török W; Petrovics-Balog A; Vígh L; Vécsei L; Balogh G
    Sci Rep; 2020 Oct; 10(1):18380. PubMed ID: 33110173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
    Bartosik-Psujek H; Archelos JJ
    J Neurol; 2004 Apr; 251(4):414-20. PubMed ID: 15083285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoassay of P2 protein in cerebrospinal fluid in neurological disorders.
    Colover J
    J Clin Pathol; 1991 Jan; 44(1):69-72. PubMed ID: 1705262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    Horellou P; Wang M; Keo V; Chrétien P; Serguera C; Waters P; Deiva K
    J Neuroimmunol; 2015 Dec; 289():1-7. PubMed ID: 26616865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal activation of the complement system and disability in multiple sclerosis.
    Sellebjerg F; Jaliashvili I; Christiansen M; Garred P
    J Neurol Sci; 1998 May; 157(2):168-74. PubMed ID: 9619641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid lipids in demyelinating disease. I. Sphingolipids.
    Seidel D; Buck R; Heipertz R; Pilz H
    J Neurol; 1980 Jan; 222(3):171-6. PubMed ID: 6153704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agarose electrophoresis and immunonephelometric quantitation of cerebrospinal fluid immunoglobulins: criteria for application in the diagnosis of neurologic disease.
    Pearl GS; Check IJ; Hunter RL
    Am J Clin Pathol; 1984 May; 81(5):575-80. PubMed ID: 6720628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligoclonal bands and quantitation of IgG in cerebrospinal fluid as indicators of multiple sclerosis.
    Gerson B; Orr JM
    Am J Clin Pathol; 1980 Jan; 73(1):87-91. PubMed ID: 7352429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of cerebrospinal fluid evaluation.
    Fredrikson S
    Int MS J; 2010 Jan; 17(1):24-7. PubMed ID: 20663418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of cerebrospinal fluid myelin basic protein in patients with neurological illness.
    Davies L; McLeod JG; Muir A; Hensley WJ
    Clin Exp Neurol; 1987; 24():5-10. PubMed ID: 2478320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.